Evaluation of Safety & Efficacy of Bispecific & CAR T Therapies in Humanized Mice

Time: 8:00 am
day: Day One


  • Novel in vivo model for cytokine release syndrome to de-risk antibody and cellular therapies for pre-clinical development
  • Evaluate drug effects on individual PBMC donors
  • Determine drug dose-response with efficacy and safety